Adenomyosis

1. Clinical Overview

Summary

Adenomyosis is a common benign gynaecological condition characterized by the presence of endometrial glands and stroma within the myometrium (uterine muscle layer), located at least 2.5mm below the endometrial-myometrial junction. This ectopic endometrial tissue responds to hormonal fluctuations throughout the menstrual cycle, leading to cyclical bleeding within the myometrium, reactive smooth muscle hyperplasia, and characteristic clinical manifestations. [1,2]

The condition predominantly affects multiparous women in their late reproductive years (40-50 years), though increasing recognition through advanced imaging has identified cases in younger women and nulliparous individuals. The classic clinical triad consists of:

1. Heavy menstrual bleeding (menorrhagia) - affecting 40-60% of patients
2. Painful periods (dysmenorrhoea) - affecting 15-30% of patients
3. Uniformly enlarged, tender uterus on examination [3,4]

Adenomyosis represents a significant clinical challenge due to its heterogeneous presentation, frequent coexistence with other gynaecological pathology (particularly endometriosis in 20-55% of cases and uterine fibroids in 50-70%), and impact on quality of life and reproductive outcomes. [5] The condition is oestrogen-dependent and typically regresses after menopause, providing important prognostic information for counselling patients regarding conservative management approaches.

Historically diagnosed only through histological examination of hysterectomy specimens, modern imaging modalities—particularly transvaginal ultrasound (TVUS) and magnetic resonance imaging (MRI)—now enable non-invasive diagnosis with high sensitivity (65-87%) and specificity (65-98%), transforming clinical management pathways. [6,7]

Clinical Pearls

"Boggy Uterus" Sign: On bimanual examination, the adenomyotic uterus characteristically feels soft, spongy ("boggy"), and tender—distinctly different from the firm, rubbery consistency of leiomyomas. This finding, combined with symmetric enlargement, is pathognomonic.

Junctional Zone > 12mm: The MRI hallmark of adenomyosis. The junctional zone represents the inner third of the myometrium; thickening beyond 12mm has 85-96% specificity for adenomyosis. [8]

LNG-IUS First-Line: The levonorgestrel-releasing intrauterine system (Mirena) represents first-line medical management, reducing menstrual blood loss by 71-96% and significantly improving dysmenorrhoea through local endometrial suppression. [9]

Hysterectomy as Definitive Treatment: Unlike medical therapies which provide symptomatic relief, hysterectomy remains the only definitive cure, with patient satisfaction rates exceeding 90% in women with completed families. [10]

Fertility Implications: While historically controversial, emerging evidence suggests adenomyosis adversely affects reproductive outcomes, with reduced implantation rates (RR 0.79), increased miscarriage rates (RR 1.37), and lower live birth rates in IVF cycles. [11]

2. Epidemiology

Prevalence and Incidence

The true prevalence of adenomyosis remains challenging to determine due to:

• Historical reliance on histological diagnosis post-hysterectomy
• Variable diagnostic criteria across imaging modalities
• Asymptomatic disease in 33% of cases
• Frequent coexistence with other pelvic pathology [12]

The incidence increases with age, peaking in the fifth decade of life (45-50 years), reflecting cumulative oestrogen exposure and reproductive events. [13]

Demographics

Risk Factors

Exam Detail: MRCOG Examination Focus: Understand that the aetiology of adenomyosis remains incompletely understood, with multiple theories proposed:

1. Tissue Invasion Theory: Direct invagination of basalis endometrium into myometrium through defects in the JZ (supported by association with surgical trauma)
2. De Novo Metaplasia Theory: Müllerian remnants within myometrium undergo metaplastic transformation to endometrial tissue (explains cases without surgical history)
3. Stem Cell Theory: Bone marrow-derived stem cells differentiate into endometrial tissue within myometrium (emerging evidence)
4. Lymphovascular Metastasis: Endometrial tissue transported via lymphatic/vascular channels (parallel to endometriosis pathogenesis)

The disrupted JZ hypothesis is most widely accepted, explaining associations with parity, uterine surgery, and age. However, cases in young nulliparous women suggest multifactorial aetiology.

Associated Conditions

3. Pathophysiology

Molecular and Cellular Mechanisms

Adenomyosis represents a complex disorder involving aberrant endometrial-myometrial interface, altered hormone signalling, chronic inflammation, and smooth muscle dysfunction. [14,15]

Hormonal Dysregulation

Oestrogen Hypersensitivity:

• Increased expression of oestrogen receptor-β (ER-β) in ectopic endometrium
• Enhanced aromatase activity in adenomyotic lesions → local oestrogen synthesis from androgens
• Reduced 17β-hydroxysteroid dehydrogenase type 2 (converts E2 to weaker E1) → accumulation of active oestradiol
• Upregulated steroidogenic acute regulatory protein (StAR) → enhanced local steroid production

Progesterone Resistance:

• Decreased progesterone receptor (PR) expression in eutopic and ectopic endometrium
• Altered PR-A/PR-B ratio → impaired progesterone signalling
• Reduced expression of progesterone-responsive genes
• This explains variable response to progestogenic therapies

Inflammatory Mediators

Adenomyosis is characterized by a chronic inflammatory milieu:

• Elevated prostaglandin E2 (PGE2) and prostaglandin F2α → uterine hypercontractility, pain, increased bleeding
• Increased cyclooxygenase-2 (COX-2) expression in glandular and stromal components
• Elevated interleukin-6 (IL-6), IL-8, tumor necrosis factor-α (TNF-α) → chronic inflammation
• Increased nerve growth factor (NGF) → nociceptor sensitization, neuroangiogenesis
• Aberrant matrix metalloproteinase (MMP) expression (MMP-2, MMP-9) → enhanced tissue invasion

Angiogenesis and Vascular Dysfunction

• Elevated vascular endothelial growth factor (VEGF) → abnormal vascular proliferation
• Increased hypoxia-inducible factor-1α (HIF-1α) in hypoxic adenomyotic foci
• Aberrant vascular architecture → increased menstrual blood loss
• Neuroangiogenesis (concurrent nerve and vessel growth) → pain generation

Myometrial Changes

• Smooth muscle hyperplasia: Reactive proliferation surrounding ectopic endometrium
• Altered contractility: Dysregulated oxytocin receptor expression, gap junction dysfunction
• Fibrosis: Increased collagen deposition, particularly in long-standing disease
• Oxidative stress: Elevated reactive oxygen species (ROS) → cellular damage

Exam Detail: Viva Question: "Explain the molecular basis of progesterone resistance in adenomyosis."

Model Answer: Progesterone resistance in adenomyosis involves multiple mechanisms:

1. Receptor alterations: Decreased total PR expression and altered PR-A/PR-B ratios impair normal progesterone signalling. PR-B typically mediates proliferative effects, while PR-A has inhibitory functions.

2. Coactivator/corepressor imbalance: Altered expression of PR coregulators affects transcriptional activity despite adequate receptor levels.

3. Inflammatory interference: Chronic elevation of inflammatory cytokines (IL-6, TNF-α) interferes with PR signalling pathways.

4. Epigenetic modifications: DNA methylation and histone modifications alter PR gene expression and progesterone-responsive gene activation.

This resistance explains why high-dose progestogenic therapies show variable efficacy, with only 60-70% of women achieving satisfactory symptom control, compared to > 80% in simple endometrial hyperplasia where PR function is intact.

Gross and Microscopic Pathology

Macroscopic Features

Gross Appearance:

• Diffuse adenomyosis: Uniformly enlarged uterus with thick, boggy myometrium
• Cut surface shows trabeculated appearance with hemorrhagic foci
• Focal adenomyosis (adenomyoma): Circumscribed nodular lesion (1-5cm), poorly demarcated from surrounding myometrium
• Absence of pseudocapsule (unlike leiomyomas)
• Uterine size: Typically 150-300g (normal 70-80g), may reach 400-500g in severe cases

Microscopic Features

Histological Criteria (Essential for Diagnosis):

1. Presence of endometrial glands and stroma within the myometrium
2. Depth criterion: Located > 2.5mm (approximately one low-power field) below the endometrial-myometrial junction
3. Surrounding smooth muscle hyperplasia and hypertrophy

Subtypes by Depth:

Types by Distribution:

1. Diffuse adenomyosis: Widespread involvement of myometrium (70-80% of cases)
2. Focal/adenomyoma: Localized nodular lesion (20-30%)
3. Adenomyotic cysts: Hemorrhagic cystic spaces within myometrium (seen in 10-15%)

Anatomical Considerations

Junctional Zone Anatomy:

• The junctional zone (JZ) represents the inner third of myometrium, immediately subjacent to the endometrium
• Histologically: Inner compact layer with tightly arranged circular smooth muscle fibers
• Normal JZ thickness: 5-8mm on MRI (varies with menstrual cycle phase)
• Adenomyosis: JZ thickening > 12mm (diagnostic); irregular architecture; loss of normal low-signal intensity on T2-weighted MRI

Distribution Patterns:

• Anterior wall predominance: 60-70% of cases (may reflect surgical trauma from C-sections)
• Posterior wall: 20-30%
• Fundal: 10-15%
• Asymmetric involvement common (unlike diffuse smooth muscle hypertrophy)

Pathophysiological Sequelae

Abnormal Uterine Bleeding Mechanisms

1. Increased endometrial surface area: Ectopic endometrium in myometrium adds to total menstruating tissue
2. Vascular proliferation: VEGF-driven neovascularization creates fragile, dilated vessels
3. Impaired haemostasis: Dysregulated fibrinolytic activity (increased plasminogen activator)
4. Abnormal uterine contractility: Impaired myometrial contraction fails to compress spiral arteries post-menstruation
5. Prostaglandin effects: Elevated PGE2 causes vasodilatation

Pain Generation Mechanisms

1. Cyclical hemorrhage: Bleeding into myometrium → distension, inflammation, pain
2. Myometrial hypercontractility: Elevated PGF2α → dysrhythmic contractions, ischemia-reperfusion injury
3. Neuroangiogenesis: Ingrowth of sensory nerve fibers (substance P, CGRP immunoreactive) alongside vessels
4. Central sensitization: Chronic pain → altered CNS processing, lowered pain threshold
5. Inflammatory mediators: IL-1β, IL-6, TNF-α directly activate nociceptors

Reproductive Dysfunction Mechanisms

Emerging evidence suggests multiple pathways affecting fertility: [11,16]

1. Impaired implantation:

   • Altered endometrial receptivity (aberrant HOXA10, integrin expression)
   • Dysregulated endometrial-embryo dialogue
   • Chronic inflammatory environment toxic to embryo

2. Altered uterine contractility:

   • Dysrhythmic contractions impair sperm transport
   • Abnormal junctional zone function disrupts embryo-endometrial apposition

3. Mechanical distortion:

   • Severe disease distorts endometrial cavity
   • Impaired implantation site perfusion

4. Oxidative stress:

   • Elevated ROS → DNA damage in oocytes, embryos
   • Impaired mitochondrial function

5. Hormonal dysregulation:

   • Local progesterone resistance → impaired decidualization
   • Altered endometrial preparation for implantation

4. Differential Diagnosis

Comprehensive Differential

Adenomyosis vs Fibroids: Critical Distinction

This comparison is high-yield for MRCOG examinations:

Clinical Pearl: Clinical Distinction Tip: If on bimanual examination you palpate a uterus that feels like "a bag of marbles" (multiple discrete firm nodules), think fibroids. If it feels like "a water-logged sponge" (diffusely soft and boggy), think adenomyosis. This tactile distinction is invaluable in clinical examinations.

Coexistence Patterns

Adenomyosis frequently coexists with other pathology, complicating diagnosis and management:

MRCOG Tip: When a patient presents with both adenomyosis and fibroids, MRI is invaluable for pre-operative planning. Document which pathology is likely the dominant contributor to symptoms to guide treatment selection.

5. Clinical Presentation

Symptom Profile

Adenomyosis demonstrates a bimodal presentation pattern:

1. Asymptomatic (33%): Incidental finding on imaging or hysterectomy
2. Symptomatic (67%): Ranging from mild to severely disabling

Symptom Patterns by Age

Clinical Pearl: "Clot Clinic" Red Flag: Women describing passing large clots (> 50p coin size), flooding through overnight protection, or experiencing flooding events necessitating clothing changes warrant urgent assessment for anaemia and underlying structural pathology. Check FBC, ferritin, and imaging urgently.

Physical Examination Findings

Bimanual Pelvic Examination

Speculum Examination

Usually normal in isolated adenomyosis:

• Cervix appears normal
• No abnormal discharge
• No contact bleeding (if present, investigate for cervical/endometrial pathology)

Red Flag: Any postmenopausal bleeding or abnormal cervical appearance requires urgent investigation regardless of adenomyosis diagnosis.

Timing of Examination

Exam Detail: Optimal Examination Timing: The adenomyotic uterus is most characteristic premenstrually (days 21-28 of cycle) when maximal hormonal stimulation and venous congestion accentuate the boggy texture and tenderness. Examination during menses may be uncomfortable; mid-cycle examination may underestimate findings.

Special Populations

Adenomyosis and Infertility

Recent meta-analyses have established adenomyosis as an independent factor affecting reproductive outcomes: [11,16]

Proposed Mechanisms:

• Altered endometrial receptivity (aberrant implantation window)
• Dysregulated uterine contractility (impaired embryo transport and retention)
• Chronic inflammatory environment
• Local progesterone resistance (impaired decidualization)

Clinical Implications for IVF:

• Consider pre-treatment GnRH agonist suppression (2-6 months) to down-regulate disease
• Optimize medical control (LNG-IUS, COCP) for at least 3 months before ART
• Counsel regarding increased miscarriage risk and consider close surveillance in early pregnancy
• Consider immunomodulation (prednisolone, intralipids) in recurrent failure, though evidence limited

Adolescent Adenomyosis

Increasingly recognized with advanced imaging; previously thought rare:

• Often presents with severe dysmenorrhoea refractory to NSAIDs and COCP
• May be associated with congenital uterine anomalies (particularly obstructive)
• Diagnosis challenging; high index of suspicion required
• MRI valuable in this population
• Medical management preferred; preserve fertility potential

6. Investigations

Diagnostic Approach

CLINICAL SUSPICION OF ADENOMYOSIS
(HMB, dysmenorrhoea, boggy tender uterus)
              ↓
        FIRST-LINE IMAGING
   Transvaginal Ultrasound (TVUS)
              ↓
    ┌─────────┴─────────┐
    ↓                   ↓
DIAGNOSTIC         EQUIVOCAL/UNCERTAIN
    ↓                   ↓
MANAGE          MRI PELVIS
                (Gold standard imaging)
                        ↓
                  CONFIRM DIAGNOSIS
                        ↓
              EXCLUDE COEXISTENT PATHOLOGY
        (Fibroids, polyps, endometrial hyperplasia)
                        ↓
                ASSESS SYMPTOM SEVERITY
                        ↓
                COUNSEL AND MANAGE

Imaging Modalities

Transvaginal Ultrasound (TVUS)

First-line investigation; non-invasive, widely available, cost-effective. [6,7]

Diagnostic Criteria (MUSA Consensus 2015):

Performing Quality TVUS for Adenomyosis:

1. Use high-frequency probe (5-9 MHz)
2. Examine in early follicular phase (days 5-10) when endometrium thin
3. Assess endometrial-myometrial junction systematically
4. Measure myometrial thickness (anterior and posterior walls)
5. Use color Doppler to assess vascularity
6. Document presence/absence of fibroids, polyps, free fluid

Ultrasound Classification:

• Mild: 1-2 features present
• Moderate: 3-4 features present
• Severe: ≥5 features; extensive involvement; distorted anatomy

Limitations:

• Operator-dependent: Requires experience
• Obesity: Image quality degraded in high BMI (> 35)
• Coexistent fibroids: Difficult to distinguish adenomyoma from fibroid
• Retroverted uterus: May limit visualization

Magnetic Resonance Imaging (MRI)

Gold standard imaging for adenomyosis; superior soft-tissue contrast. [8]

Diagnostic Criteria:

MRI Protocol:

• T2-weighted imaging: Primary sequences; demonstrates JZ anatomy optimally
• T1-weighted imaging: Detects hemorrhage (high signal on T1)
• T1 fat-saturated: Confirms hemorrhagic foci
• Dynamic contrast: Not routinely required; may help distinguish from leiomyosarcoma if suspicion

Advantages:

• Objective measurement: JZ thickness quantifiable
• Distinguishes coexistent pathology: Excellent fibroid vs adenomyoma differentiation
• Pre-surgical planning: Detailed anatomical mapping
• Not operator-dependent: Reproducible
• Detects deep endometriosis: Comprehensive pelvic assessment

Indications for MRI:

1. Equivocal USS findings
2. Coexistent fibroids requiring surgical planning (myomectomy vs hysterectomy decision)
3. Subfertility workup (assess severity, guide treatment)
4. Adenomyoma vs fibroid distinction
5. Suspicion of leiomyosarcoma (rapid growth, postmenopausal)
6. Pre-treatment assessment for fertility-sparing procedures

Limitations:

• Cost: Significantly more expensive than USS
• Availability: Limited access in some regions
• Contraindications: Metallic implants, pacemakers, claustrophobia
• Cycle variability: JZ thickness varies with menstrual cycle (thickest in luteal phase)

Exam Detail: MRCOG Viva Question: "A 38-year-old woman has been referred with heavy periods. TVUS shows a globular uterus with myometrial heterogeneity. Should you request an MRI?"

Model Answer: "The decision depends on several factors:

I would proceed directly to treatment (e.g., LNG-IUS trial) without MRI if:

• Diagnosis of adenomyosis reasonably confident on TVUS
• No suspicion of coexistent pathology requiring clarification
• Patient desires medical management
• Hysterectomy not being considered

I would request MRI if:

• USS equivocal and diagnosis uncertain
• Coexistent fibroids and considering myomectomy (need precise mapping)
• Patient desires fertility and considering fertility-sparing surgery
• Rapid uterine growth or suspicion of malignancy
• Subfertility context requiring detailed assessment
• Medical management failed and planning hysterectomy with complex anatomy

MRI adds significant information for surgical decision-making but is unnecessary for initiating medical therapy when clinical and USS findings are concordant."

Laboratory Investigations

No specific blood tests diagnose adenomyosis; investigations target complications and differential diagnosis:

Note on CA-125: Elevated CA-125 in adenomyosis reflects chronic inflammatory state and peritoneal irritation. Levels typically less than 100 U/mL (vs > 200-500 in ovarian cancer). Should NOT be used diagnostically for adenomyosis given poor specificity.

Histopathology

Historical Gold Standard (now largely replaced by imaging):

Hysterectomy Specimen Examination:

• Macroscopic features: Enlarged uterus, thickened myometrium, hemorrhagic foci
• Histological criteria:
  • Endometrial glands and stroma present in myometrium
  • Located ≥2.5mm (1 low-power field) below endometrial-myometrial junction
  • Surrounded by smooth muscle hyperplasia/hypertrophy

Endometrial Biopsy:

• Does NOT diagnose adenomyosis (samples only endometrial cavity)
• Performed to exclude endometrial hyperplasia/cancer when thickened endometrium or risk factors present

Hysteroscopy:

• Useful to exclude endometrial polyps, submucous fibroids, intrauterine adhesions
• May show endometrial openings ("pits") in adenomyosis (10-15% of cases) - endometrial glands opening into myometrium
• Not sensitive/specific for adenomyosis diagnosis

7. Management

Principles of Management

Management of adenomyosis is individualized and depends on:

1. Symptom severity (mild, moderate, severe)
2. Fertility desires (future pregnancy planned vs family complete)
3. Age and proximity to menopause (5-10 years to menopause may favor conservative approach)
4. Coexistent pathology (fibroids, endometriosis, polyps)
5. Previous treatment responses
6. Patient preferences (medical vs surgical; conservative vs definitive)

No treatment is curative except hysterectomy; medical therapies provide symptom control.

Management Algorithm

CONFIRMED ADENOMYOSIS
(Imaging ± clinical diagnosis)
           ↓
    ASSESS PRIORITIES
           ↓
  ┌────────┴────────┐
  ↓                 ↓
FERTILITY      NO FURTHER CHILDREN
DESIRED        (Family complete)
  ↓                 ↓
  │           SYMPTOM SEVERITY?
  │                 ↓
  │      ┌──────────┼──────────┐
  │      ↓          ↓          ↓
  │    MILD     MODERATE    SEVERE
  │      ↓          ↓          ↓
  │   MEDICAL   MEDICAL   PROXIMITY TO
  │   MANAGEMENT  ±       MENOPAUSE?
  │      ↓     INTERVENTION   ↓
  │      │          ↓      ┌──┴──┐
  │      │          │      ↓     ↓
  │      │          │    less than 5yr  > 5yr
  │      │          │      ↓     ↓
  └──────┴──────────┴─→ SURGERY MEDICAL
                                 ↓
                          If fails →
                             SURGERY

Medical Management

First-Line: Levonorgestrel Intrauterine System (LNG-IUS)

Mirena 52mg (or Kyleena 19.5mg) represents first-line medical therapy. [9]

Mechanism:

• Local progestogenic effect: Profound endometrial suppression (glandular atrophy, stromal decidualization)
• Suppression of ectopic endometrium: Atrophy of adenomyotic foci
• Anti-inflammatory: Reduces local prostaglandin, cytokine production
• Minimal systemic absorption: Avoids systemic progestogenic side effects

Efficacy:

Practical Use:

• Insert ideally during menses (cervix dilated, rule out pregnancy)
• Warn regarding initial irregular bleeding (first 3-6 months; 80% experience spotting)
• Counselling critical: "Things often worse before better"; bleeding settles by 6 months in most
• Analgesia during insertion (local anesthetic, misoprostol, NSAIDs)
• Review at 6 weeks, then 6 months, then annually
• Licensed for 5 years; effective for up to 8 years (off-license)

Side Effects:

Contraindications:

• Current pregnancy
• Active pelvic infection (treat, then insert)
• Undiagnosed abnormal vaginal bleeding (investigate first)
• Current breast cancer
• Distorted uterine cavity (severe adenomyosis/fibroids may prevent placement; hysteroscopic insertion may be feasible)

Clinical Pearl: Counselling Script: "The Mirena coil works by thinning the lining of your womb and the adenomyosis tissue. For the first 3-6 months, your bleeding pattern may be erratic—it can seem worse before it gets better. By 6 months, most women have very light periods or no periods at all. About 80% of women are very satisfied with it after a year. If we can get you through those first few months, it's likely to work really well."

Second-Line Medical Options

Third-Line: GnRH Agonists

Goserelin (Zoladex), Leuprolide

Mechanism:

• Initial flare: Surge in FSH/LH (first 7-10 days)
• Downregulation: Desensitization of pituitary GnRH receptors → hypogonadotrophic hypogonadism
• Medical menopause: Oestradiol less than 100 pmol/L; endometrial/adenomyosis atrophy

Efficacy:

• Uterine volume reduction: 30-50% reduction by 3 months
• Symptom improvement: 80-90% reduction in bleeding and pain
• Duration of effect: Temporary; symptoms recur 3-6 months after cessation

Indications (limited by side effects):

1. Bridge to menopause: Women within 2-3 years of menopause; buy time for natural oestrogen decline
2. Pre-operative optimization: 3-6 months before surgery to reduce uterine size, improve anemia
3. Fertility treatment: 2-6 months suppression before IVF may improve outcomes (controversial; limited evidence)

Administration:

• Goserelin 3.6mg SC monthly (or 10.8mg depot 3-monthly)
• Leuprolide 3.75mg IM monthly
• Add-back HRT after 6 months if continuing (see below)

Side Effects:

Add-Back HRT (to mitigate side effects while maintaining efficacy):

• Regimen: Tibolone 2.5mg daily OR continuous combined HRT (e.g., E2 2mg + norethisterone 1mg)
• Rationale: Partial oestrogen replacement (to "perimenopausal" rather than "postmenopausal" levels) reduces side effects while maintaining therapeutic effect on adenomyosis
• Evidence: Maintains 70-80% symptom improvement while dramatically reducing vasomotor symptoms and BMD loss
• Start timing: From outset (enable longer duration) or after 6 months

Duration:

• Without add-back: Maximum 6 months (BMD concerns)
• With add-back: Up to 12-24 months (individualized; off-license)

Cost and Availability:

• More expensive than LNG-IUS/COCP
• Usually secondary care initiated
• Not suitable for long-term maintenance

Exam Detail: Viva Question: "Why can't we use GnRH agonists long-term for adenomyosis?"

Model Answer: "GnRH agonists induce a profound hypooestrogenic state analogous to menopause. This causes:

1. Bone mineral density loss: Approximately 5-10% loss in the first 6 months, increasing fracture risk if prolonged. This is the primary limiting factor.

2. Vasomotor symptoms: Hot flushes and night sweats affect 80-90% of women, significantly impacting quality of life.

3. Cardiovascular concerns: Prolonged hypoestrogenism may adversely affect lipid profiles and endothelial function.

4. Genitourinary symptoms: Vaginal atrophy, urinary symptoms.

5. Symptom recurrence: Effects are temporary; symptoms recur within 3-6 months of stopping, so ongoing treatment would be required indefinitely.

To extend duration, we can use add-back HRT, which partially replaces oestrogen to 'perimenopausal' rather than 'postmenopausal' levels. This mitigates side effects and BMD loss while maintaining 70-80% therapeutic efficacy, enabling use for 12-24 months in selected cases. However, this remains an expensive option compared to LNG-IUS, and symptom recurrence on cessation remains an issue.

Therefore, GnRH agonists are best used as:

• Bridge therapy to menopause in women within 2-3 years
• Pre-operative optimization for 3-6 months before surgery
• Short-term rescue when other options have failed and surgery is being considered"

Emerging/Experimental Medical Therapies

Interventional (Non-Excisional) Treatments

Uterine Artery Embolization (UAE)

Mechanism: Radiological occlusion of uterine arteries with embolic particles → ischemic necrosis of adenomyotic tissue.

Procedure:

• Femoral artery catheterization under local anesthesia ± sedation
• Selective catheterization of uterine arteries bilaterally
• Injection of embolic particles (300-500 μm polyvinyl alcohol or trisacryl gelatin microspheres)
• Same-day or overnight stay

Efficacy for Adenomyosis:

Success Predictors (Worse outcomes if):

• Diffuse adenomyosis (vs focal adenomyoma)
• JZ > 15mm (extensive disease)
• Coexistent fibroids (difficult to attribute benefit)

Advantages:

• Uterine preservation (fertility potential maintained, though limited data)
• Avoids general anesthesia and laparotomy
• Outpatient/short stay

Complications:

Contraindications:

• Active pelvic infection
• Pregnancy/attempting pregnancy imminently (caution; case reports of pregnancy post-UAE but limited data)
• Contrast allergy (relative; manageable)
• Renal impairment (contrast nephropathy risk)

Current Role: Second-line option for women desiring uterine preservation who have failed medical management or cannot tolerate it; counsel regarding lower success rate than for fibroids and limited fertility data.

Endometrial Ablation

AVOID in adenomyosis (NICE guidance, RCOG consensus).

Rationale:

• Adenomyosis is deep within myometrium; endometrial ablation only treats surface 4-6mm
• Risk of trapped blood: Ablation scars endometrial-myometrial junction; deep adenomyotic foci continue to bleed cyclically → blood trapped within myometrium → hematometra, chronic pain, need for hysterectomy
• High failure rate: 30-50% require re-intervention within 2-5 years (vs 10-20% in normal uterus)

Complication Risk: Post-ablation pain syndrome occurs in up to 10-15% of women with adenomyosis (vs 2-5% in those without).

Conclusion: Endometrial ablation is contraindicated in known adenomyosis and should be avoided.

MRI-Guided Focused Ultrasound (MRgFUS)

Mechanism: High-intensity focused ultrasound thermally ablates adenomyotic tissue under MRI guidance.

Status: Experimental for adenomyosis; limited evidence.

• Small studies show 50-70% symptom improvement at 6-12 months
• Non-invasive; preserves uterus
• Requires specialized equipment (limited availability)
• Long-term outcomes unknown
• May be considered in research/specialist centers for women desiring uterine preservation who have failed other options

Surgical Management

Hysterectomy

The ONLY definitive cure for adenomyosis. [10]

Indications:

• Family complete (no further fertility desired)
• Severe symptoms refractory to medical management
• Failed medical/interventional therapies
• Patient preference (informed choice after counselling)
• Coexistent pathology requiring surgical management (e.g., large fibroids, complex hyperplasia)

Approaches:

Ovarian Conservation:

• Premenopausal women: Conserve ovaries unless specific indication (family history BRCA, severe endometriosis)
• Ovarian conservation avoids surgical menopause, preserves cardiovascular and bone health
• Ovarian cancer risk NOT increased by ovarian conservation in absence of genetic risk
• Postmenopausal: Consider bilateral salpingo-oophorectomy (BSO) (reduces ovarian cancer risk)

Outcomes:

Complications:

Counselling Points:

• Permanent loss of fertility: Irreversible; ensure certainty
• No further periods: Amenorrhoea
• Sexual function: Usually improves (pain resolution); some report decreased libido; vaginal vault may be shorter
• Psychological impact: Variable; some women experience sense of loss; offer psychology support if needed
• Recovery: Typically 6-8 weeks to full activity; earlier return with minimally invasive approaches
• Hormone replacement: If premenopausal and ovaries conserved, NOT required unless premature ovarian insufficiency develops

Clinical Pearl: Counselling Approach: "Hysterectomy is a big operation, but for adenomyosis that has failed all other treatments, it is the only way to guarantee cure. Your periods will stop permanently, and you won't be able to have children in the future—so we need to be certain your family is complete. Most women (9 out of 10) are very satisfied after surgery because the heavy bleeding and pain resolve. Recovery takes about 6-8 weeks. If we preserve your ovaries, you won't go through menopause early. What questions do you have?"

Adenomyomectomy and Fertility-Sparing Surgery

Rationale: Excise adenomyotic tissue while preserving uterus for future fertility.

Indications (highly selective):

• Focal adenomyosis (adenomyoma) rather than diffuse disease
• Strong desire for future fertility
• Failed medical management
• Coexistent with fibroids requiring myomectomy

Techniques:

1. Cytoreductive surgery: Excision of adenomyotic tissue (difficult due to ill-defined borders; not encapsulated like fibroids)
2. Wedge resection: Removal of involved myometrial segment
3. Myometrial electrocoagulation/excision: Laparoscopic or open

Challenges:

• Ill-defined borders: Unlike fibroids, no clear plane between adenomyosis and normal myometrium
• Incomplete excision: Difficult to ensure complete removal; high recurrence risk
• Uterine integrity: Extensive excision → thin myometrium → rupture risk in pregnancy

Outcomes:

Current Status: Experimental; performed in specialist centers; limited long-term data.

Conclusion: Reserve for highly motivated patients with focal disease after extensive counseling regarding risks and uncertain benefits. Most gynecologists favor medical management or proceeding to hysterectomy over adenomyomectomy.

8. Complications and Long-Term Sequelae

Direct Complications of Disease

Reproductive Complications

Exam Detail: MRCOG Question: "A 35-year-old woman with known adenomyosis (JZ 14mm on MRI) is undergoing IVF after 3 years of infertility. What would you counsel her regarding her prognosis?"

Model Answer: "I would provide evidence-based counseling on how adenomyosis may affect IVF outcomes:

Impact on IVF Success:

• Meta-analyses show adenomyosis reduces implantation rates by approximately 20% (RR 0.79)
• Clinical pregnancy rates are reduced by about 12% (RR 0.88)
• Miscarriage risk is increased by 37% (RR 1.37)
• Overall, live birth rates are reduced by approximately 15% (RR 0.85)

Optimization Strategies (though evidence limited):

1. Consider 2-6 months GnRH agonist pre-treatment to downregulate adenomyosis
2. Ensure medical control with LNG-IUS or COCP for at least 3 months before stimulation
3. Optimize transfer technique (avoid myometrial trauma)
4. Consider elective single embryo transfer of highest quality blastocyst

Pregnancy Monitoring:

• Early viability scan at 6-7 weeks (increased miscarriage risk)
• Reassess risk factors for placental complications (previa, adherent placenta)
• Monitor fetal growth (possible increased FGR risk)

Realistic Expectations:

• Success is still achievable but may require more cycles
• If recurrent implantation failure, could revisit additional interventions

I would emphasize that while adenomyosis does impact outcomes, many women with adenomyosis achieve successful pregnancies with IVF, and individualizing her treatment plan with her fertility specialist is important."

Complications of Treatment

9. Prognosis and Natural History

Natural History

Adenomyosis is an oestrogen-dependent condition; its natural course is dictated by hormonal milieu:

Key Point: Women within 5-10 years of menopause may opt for conservative management (LNG-IUS, GnRH agonists with add-back) to "bridge" to natural symptom resolution, avoiding surgery.

Prognosis by Treatment Modality

Factors Affecting Prognosis

Favorable Prognostic Factors (better response to medical management):

• Focal disease (adenomyoma) vs diffuse
• Mild-moderate severity (JZ 8-14mm)
• Younger age (time for optimization before definitive treatment)
• Proximity to menopause (natural resolution impending)
• Isolated adenomyosis (no coexistent fibroids/endometriosis complicating picture)

Unfavorable Prognostic Factors (more likely to require surgery):

• Diffuse severe disease (JZ > 15mm)
• Coexistent multiple pathologies (fibroids, endometriosis, polyps)
• Young age with severe symptoms (long reproductive lifespan requiring management)
• Failed multiple medical therapies
• Severe impact on quality of life (unable to work, function)

Long-Term Outcomes

Quality of Life:

• Untreated symptomatic adenomyosis significantly impairs HRQoL across physical, emotional, social, and work domains
• Effective treatment (medical or surgical) results in substantial improvement in validated QoL scores (EQ-5D, SF-36)
• Hysterectomy shows greatest magnitude of improvement and durability

Fertility:

• Natural fertility outcomes in women with adenomyosis not well characterized (difficult to isolate effect)
• IVF outcomes reduced but pregnancies achievable (see earlier section)
• Post-treatment (adenomyomectomy) pregnancy outcomes highly variable (40-60% pregnancy rate; high recurrence)

Cancer Risk:

• Adenomyosis is benign; no malignant transformation
• No increased risk of endometrial or ovarian cancer
• Coexistence with endometrial cancer reported but likely coincidental (both oestrogen-related)

10. Prevention and Screening

Primary Prevention

No established primary prevention strategies as aetiology incompletely understood.

Theoretical risk reduction (limited evidence):

• Minimizing uterine trauma: Limit unnecessary uterine instrumentation (D&C, hysteroscopy); optimize delivery technique to minimize myometrial injury
• Hormonal contraception: Some evidence that long-term COCP or LNG-IUS use may reduce risk through endometrial suppression (not proven)

Secondary Prevention (Early Detection)

No population screening (not cost-effective; large asymptomatic population).

Opportunistic case-finding:

• High index of suspicion in women presenting with HMB + dysmenorrhoea + bulky uterus
• Early TVUS in symptomatic women to diagnose while disease mild (earlier intervention may improve outcomes)
• Consider adenomyosis in infertility workup, particularly if recurrent IVF failure

Tertiary Prevention (Preventing Complications)

• Treat anaemia: Regular FBC monitoring in women with HMB; iron supplementation; treat underlying bleeding
• Optimize fertility: Early diagnosis in subfertile women; consider pre-treatment before ART
• Pain management: Multimodal analgesia; avoid opioid dependence; early escalation to specialist pain services if refractory

11. Evidence, Guidelines, and Controversies

Key Guidelines

NICE NG88 Summary:

• Offer LNG-IUS as first-line for HMB (regardless of cause including adenomyosis)
• Perform TVUS in all women with HMB to identify structural pathology
• Offer tranexamic acid or NSAIDs if LNG-IUS declined or contraindicated
• Endometrial biopsy if age ≥45 years, treatment failure, or intermenstrual bleeding
• Refer to secondary care if medical management fails, diagnostic uncertainty, or surgical management desired

Evidence Levels

Areas of Controversy and Ongoing Research

Evidence Debate: 1. Impact on Fertility: Causation vs Association?

Debate: Does adenomyosis directly cause infertility, or is the association confounded by coexistent endometriosis, age, and other factors?

Evidence For Causal Role:

• Meta-analyses show consistent association with reduced IVF outcomes [11,16]
• Plausible biological mechanisms (altered receptivity, contractility, inflammation)
• Dose-response relationship (more severe disease → worse outcomes)

Evidence Against/Confounders:

• High coexistence with endometriosis (difficult to isolate effect)
• Age confounding (adenomyosis more common in older women undergoing IVF)
• Selection bias (symptomatic women more likely diagnosed)

Current Consensus: Probable causal role, particularly in moderate-severe disease, though magnitude of effect debated.

Ongoing Research: Prospective studies adjusting for confounders; biomarkers of endometrial receptivity; trials of pre-treatment interventions.

2. Pre-IVF Treatment: Does GnRH Agonist Suppression Help?

Rationale: Downregulate adenomyosis to improve endometrial receptivity and implantation.

Evidence:

• Small retrospective studies suggest 2-6 months GnRH agonist before IVF may improve outcomes
• No large RCTs (difficult to conduct given heterogeneity of disease)
• Systematic review shows trend toward benefit but low-quality evidence

Current Practice: Variable; some fertility specialists use routinely in severe adenomyosis; others do not.

Needed: Large multicenter RCT comparing IVF outcomes with vs without pre-treatment.

3. Endometrial Ablation: Absolute Contraindication or Case-by-Case?

Consensus View: Avoid in known adenomyosis due to high complication risk (trapped blood, pain, re-intervention).

Nuance: Some argue for selective use in superficial adenomyosis (JZ 8-12mm) in carefully counseled patients who decline hysterectomy and failed medical management.

Evidence: No RCTs; case series show high complication rates; expert opinion strongly discourages.

Current Practice: Contraindicated per major guidelines (NICE, RCOG).

4. Adenomyomectomy: Experimental or Viable Option?

Enthusiasm (mainly Asia, some European centers):

• Fertility preservation critical for many women
• Focal disease (adenomyoma) potentially resectable
• Pregnancy rates 40-60% reported

Skepticism (UK, North America):

• Ill-defined borders make complete excision unlikely
• High recurrence rates (30-60%)
• Uterine rupture risk in pregnancy (1-10%)
• Limited long-term data
• Medical management and hysterectomy provide more predictable outcomes

Current Consensus: Reserve for highly selected cases in specialist centers; not standard of care; counsel extensively regarding risks.

5. Pathogenesis: One Disease or Multiple Subtypes?

Emerging Hypothesis: Adenomyosis may represent a spectrum of disease with different subtypes:

• Type 1 (Superficial): JZ disruption, associated with parity/surgery → responds well to LNG-IUS
• Type 2 (Deep): Extensive myometrial involvement → more likely requires surgery
• Type 3 (Adenomyoma): Focal nodular lesion → potentially amenable to excision

Implication: Tailored management based on subtype rather than "one size fits all."

Research Needed: Validation of classification systems; correlation with outcomes; genetic/molecular profiling.

Key Landmark Studies

12. Special Considerations

Adenomyosis in Adolescents

Changing Paradigm: Previously thought rare in adolescents; now increasingly recognized.

Presentation:

• Severe dysmenorrhoea refractory to NSAIDs and standard analgesia
• Often begins shortly after menarche (vs adult-onset which worsens progressively)
• May be associated with congenital uterine anomalies, particularly obstructive (e.g., blind uterine horn)

Diagnosis:

• High index of suspicion if severe dysmenorrhoea not responding to treatment
• MRI valuable (TVUS may be challenging in adolescents; MRI non-invasive)
• JZ thickness criteria same as adults (> 12mm diagnostic)

Management:

• Medical management preferred: LNG-IUS (may be challenging in nulliparous; consider hysteroscopic insertion), COCP (continuous), depo-provera
• GnRH agonists for severe refractory pain (short-term; add-back HRT essential)
• Surgery (hysterectomy) NOT appropriate; fertility preservation paramount
• Multidisciplinary approach: pediatric/adolescent gynecology, pain clinic, psychology

Adenomyosis and Pregnancy

Antepartum Considerations:

• Limited data on obstetric outcomes; most evidence from IVF cohorts
• Possible increased risk of:
  • Preterm birth (OR 1.5-2.0 in some studies; conflicting data)
  • Small for gestational age (impaired uteroplacental perfusion)
  • Placenta previa (OR 2.0-4.0; abnormal myometrial vascularity)
  • "Morbidly adherent placenta (spectrum: accreta, increta, percreta; disrupted JZ may predispose)"
  • Placental abruption (conflicting evidence)

Management:

• Routine antenatal care generally appropriate
• Early viability scan (increased miscarriage risk)
• Anomaly scan + placental localization at 20 weeks
• Serial growth scans if FGR risk factors or suboptimal growth
• If placenta previa: arrange MRI at 32-34 weeks if suspicion of morbidly adherent placenta (especially if prior CS); multidisciplinary planning for delivery
• Delivery: No specific indication for cesarean section unless obstetric indications (e.g., malpresentation, FGR)

Postpartum:

• Symptoms may improve during pregnancy (decidualization of ectopic tissue; progesterone dominance)
• Often recur postpartum, particularly if breastfeeding ceases (return of menstruation)
• Re-initiate medical management (LNG-IUS can be inserted at 6-week check)

Postmenopausal Adenomyosis

Expected Natural History: Symptoms should resolve with menopause (oestrogen withdrawal).

Persistent Symptoms Postmenopause:

• Red flag: Postmenopausal bleeding is NEVER due to adenomyosis alone
• Differential: Endometrial cancer, polyps, atrophic endometritis, HRT-related bleeding, cervical cancer
• Investigate urgently: TVUS (endometrial thickness), endometrial biopsy, hysteroscopy

Adenomyosis on Imaging in Postmenopausal Women:

• May be incidental finding (historical disease now quiescent)
• JZ thickening often regresses postmenopause but may persist
• If asymptomatic: no action required; reassure

HRT in Women with Adenomyosis:

• Not contraindicated (adenomyosis is benign)
• May cause recurrence of bleeding/pain in small proportion (5-10%)
• Use continuous combined HRT (not cyclical) to minimize bleeding
• If symptoms recur: can try different HRT formulation, add LNG-IUS, or stop HRT if tolerable

13. Patient Information and Shared Decision-Making

What is Adenomyosis? (Layperson Explanation)

Adenomyosis is a common, non-cancerous condition affecting the womb (uterus). Normally, the lining of the womb (called the endometrium) grows only on the inside surface of the womb. In adenomyosis, some of this lining tissue grows into the muscular wall of the womb itself.

Every month, during your period, this lining tissue—both inside the womb and within the muscle—responds to your hormones and bleeds. The bleeding from tissue trapped inside the muscle wall causes:

• Swelling and inflammation in the womb muscle
• Heavy, prolonged periods (menorrhagia)
• Painful, cramping periods (dysmenorrhoea)
• A tender, enlarged womb

Think of it like "endometriosis of the uterus muscle" (though they are distinct conditions).

Is Adenomyosis Cancer?

No. Adenomyosis is completely benign (non-cancerous). It does not turn into cancer. However, it can significantly affect your quality of life due to pain and heavy bleeding.

What Causes Adenomyosis?

The exact cause is not fully understood. It's more common in women who:

• Have had children (pregnancy and childbirth may disrupt the boundary between the lining and muscle)
• Have had surgery on the womb (cesarean section, D&C)
• Are in their 40s or early 50s (late reproductive years)

It seems to be driven by the hormone oestrogen, which is why symptoms usually improve after menopause.

How is Adenomyosis Diagnosed?

Your doctor will:

1. Ask about your symptoms: Heavy periods, painful periods, pelvic pain
2. Examine you: Feel your womb (often enlarged, soft, and tender)
3. Arrange an ultrasound scan (usually transvaginal ultrasound—a probe gently inserted into the vagina to get detailed images)
4. Sometimes request an MRI scan (a detailed imaging test) if the ultrasound is unclear or surgery is being considered

Will Adenomyosis Affect My Fertility?

This is an area of ongoing research. Adenomyosis may make it slightly harder to get pregnant and slightly increase the risk of miscarriage, particularly if the disease is severe. However, many women with adenomyosis have successful pregnancies.

If you're trying to conceive and have adenomyosis:

• Discuss it with your fertility specialist
• Treatments may be available to optimize your chances (e.g., hormonal treatments before IVF)
• Close monitoring in early pregnancy may be recommended

What Are My Treatment Options?

There is no cure except removing the womb (hysterectomy). However, many treatments can control symptoms effectively:

Medical (Non-Surgical) Treatments

Surgical Treatments

Endometrial Ablation (burning away womb lining) is NOT recommended for adenomyosis because the disease is deep in the muscle; ablation only treats the surface and can cause complications (trapped blood, pain).

How Do I Decide What Treatment is Right for Me?

Consider:

• Do you want more children? If yes → medical treatments (Mirena, pill, tablets); avoid hysterectomy
• How severe are your symptoms? Mild → try tablets/pill first; Severe → Mirena or stronger treatments
• How close are you to menopause? If within 5 years, symptoms will naturally improve after menopause → "bridge" with medical treatment rather than surgery
• Have you tried medical treatments? If medical treatments have failed and your family is complete, hysterectomy may be the best option

This is YOUR decision, made together with your doctor. There is no single "right" answer—it depends on your priorities, symptoms, and circumstances.

Will Adenomyosis Go Away on Its Own?

After menopause (when periods stop permanently, usually around age 50-52), adenomyosis symptoms almost always improve or disappear completely. This is because the condition is driven by oestrogen, which drops dramatically after menopause.

If you're close to menopause (within 5 years), you might choose to manage symptoms with medical treatment (like the Mirena coil) until your natural menopause, avoiding the need for surgery.

Living with Adenomyosis: Practical Tips

• Track your symptoms: Keep a diary of bleeding and pain to identify patterns and assess treatment effectiveness
• Manage heavy bleeding: Use high-absorbency protection; change frequently; consider period pants or menstrual cups
• Iron supplements: Heavy periods often cause iron deficiency; take iron tablets if prescribed to prevent tiredness
• Pain relief: Use heat pads, warm baths, over-the-counter painkillers during painful episodes
• Work/school accommodations: Discuss flexible arrangements during heavy/painful periods if needed
• Emotional support: Chronic pain and heavy bleeding affect mental health; talk to your doctor, counselor, or support groups

Where Can I Find Support?

• Endometriosis UK: endometriosis-uk.org (covers adenomyosis as well)
• Adenomyosis Advice Association: adenomyosisadviceassociation.org
• Your GP and gynecologist: Always your first point of contact

Questions to Ask Your Doctor

• What treatment do you recommend for me, and why?
• What are the chances this treatment will work?
• What are the side effects?
• If I want to have children in the future, what are my options?
• How long should I try a treatment before deciding if it's working?
• If medical treatment doesn't work, what's the next step?

14. Examination Focus (MRCOG/Postgraduate)

High-Yield Examination Topics

MRCOG Part 1 (MCQ/SBA Focus)

Key Facts to Memorize:

1. Junctional zone > 12mm on MRI is diagnostic for adenomyosis (sensitivity 85-93%, specificity 91-96%)
2. LNG-IUS is first-line medical management (NICE NG88)
3. Hysterectomy is the only cure; medical therapies are symptomatic only
4. Adenomyosis affects 40-60% with menorrhagia, 15-30% with dysmenorrhoea
5. Endometrial ablation is contraindicated due to risk of trapped blood and post-ablation pain syndrome
6. Adenomyosis reduces IVF live birth rates by approximately 15% (RR 0.85) and increases miscarriage by 37% (RR 1.37)
7. Boggy uterus = soft, tender, symmetrically enlarged (vs fibroids: firm, irregular)
8. Coexistence with endometriosis 20-55%; fibroids 50-70%
9. Oestrogen-dependent: symptoms regress after menopause
10. UAE less effective for adenomyosis (60-75% improvement) than fibroids (75-90%)

MRCOG Part 2 (Clinical/Viva Focus)

Common Viva Stations:

Exam Detail: Viva Station 1: Diagnosis and Investigation

Question: "A 42-year-old woman presents with increasingly heavy and painful periods over the last 2 years. Her GP has started her on tranexamic acid with minimal benefit. Examination reveals a 10-week size, tender, symmetrical uterus. How would you investigate?"

Model Answer: "This presentation is suggestive of adenomyosis, though the differential includes fibroids, polyps, and endometrial pathology.

Initial Investigations:

1. Full blood count: Assess for anaemia (common with menorrhagia)
2. Thyroid function: Exclude thyroid dysfunction as cause of menorrhagia
3. Transvaginal ultrasound: First-line imaging to assess myometrial texture, endometrial thickness, exclude fibroids/polyps

Ultrasound Findings Suggestive of Adenomyosis (MUSA criteria):

• Asymmetrical myometrial thickening
• Myometrial cysts (1-7mm anechoic areas)
• Irregular endometrial-myometrial junction
• Hyperechoic islands or fan-shaped shadowing
• Globular uterine configuration

Further Investigation if Indicated:

• MRI pelvis: If USS equivocal, coexistent fibroids requiring surgical planning, or considering fertility-sparing surgery. MRI is the gold standard: junctional zone > 12mm is diagnostic.
• Endometrial biopsy: NOT needed to diagnose adenomyosis (it's a myometrial condition), but indicated if age ≥45, persistent intermenstrual bleeding, or thickened endometrium on USS (> 16mm) to exclude endometrial hyperplasia/cancer.

I would counsel her regarding likely diagnosis and management options while awaiting imaging."

Viva Station 2: Medical Management

Question: "You've diagnosed adenomyosis on imaging. The patient is 44 years old, has completed her family (2 children), and wishes to avoid surgery if possible. Discuss your management."

Model Answer: "Given her age, completed family, and preference to avoid surgery, medical management is appropriate.

First-Line: Levonorgestrel IUS (Mirena)

• Mechanism: Local endometrial suppression; atrophy of ectopic endometrial tissue
• Efficacy: 71-96% reduction in menstrual blood loss; 60-80% improvement in dysmenorrhoea
• Practical: Insert during menses; warn about 3-6 months irregular bleeding before settling; review at 6 weeks, then 6 months
• Licensed for 5 years; effective up to 8 years

Counselling is critical: 'Things often worse before better; bleeding settles by 6 months in most women; 70-85% satisfied at 1 year.'

Second-Line Options if LNG-IUS Not Tolerated/Fails:

1. Combined oral contraceptive (COCP): Continuous or tricycling; effective if no contraindications (age, VTE risk, migraine with aura)
2. Oral progestogens: Norethisterone 5mg TDS days 5-26 or continuous
3. Tranexamic acid + NSAIDs: Adjuncts; reduce bleeding and pain respectively but less effective than hormonal options

Third-Line: GnRH Agonists (if severe symptoms, bridge to menopause):

• She's 44 years old; likely 7-8 years from menopause
• Could consider short-term (6-12 months) GnRH agonist with add-back HRT to control symptoms while trialing other options or if very close to menopause
• Side effects (vasomotor, BMD loss) limit long-term use

Review and Reassess:

• If medical management fails after adequate trial (6-12 months), discuss hysterectomy as definitive cure
• Highlight that she's an excellent candidate for laparoscopic hysterectomy (good BMI, mobile uterus likely, completed family); conserve ovaries (she's premenopausal); high satisfaction rates (85-95%)

Shared decision-making: Her priorities, lifestyle, symptom severity guide choice."

Viva Station 3: Adenomyosis and Infertility

Question: "A 36-year-old nulliparous woman has been diagnosed with adenomyosis (JZ 13mm on MRI) during investigation for 2 years of infertility. She has mild dysmenorrhoea but her main concern is fertility. Partner's semen analysis is normal. How do you counsel her?"

Model Answer: "This requires sensitive counseling balancing her fertility goals with the impact of adenomyosis.

Impact on Fertility:

• Recent meta-analyses show adenomyosis independently affects reproductive outcomes:
  • Implantation rate reduced by ~20% (RR 0.79)
  • Miscarriage risk increased by 37% (RR 1.37)
  • Live birth rate reduced by ~15% (RR 0.85)
• Her adenomyosis is mild-moderate (JZ 13mm); severe disease (JZ > 15mm) has worse outcomes

Management Options:

Option 1: Expectant/Timed Intercourse (if ovulating regularly):

• May conceive naturally despite adenomyosis (many women do)
• Duration of infertility (2 years) suggests reduced fertility
• Age 36: time is a factor; avoid prolonged expectancy

Option 2: Medical Suppression Before Conception Attempts:

• Some evidence (limited, mainly retrospective) that 2-6 months GnRH agonist suppression may improve endometrial receptivity
• Could consider this before proceeding to IVF
• Downside: Further delay; uncertain benefit

Option 3: Proceed to IVF:

• Given 2 years infertility, age 36, consider proceeding to ART without delay
• Adenomyosis is one of several factors affecting success (also age, ovarian reserve, embryo quality)
• Optimize: Consider short-term (2-3 months) pre-treatment with COCP or LNG-IUS (though data limited) vs proceeding directly

Option 4: Surgical Treatment (Adenomyomectomy):

• Experimental; limited data
• Ill-defined borders make complete excision difficult
• Uterine rupture risk in pregnancy (1-10%)
• Generally NOT recommended as first-line
• Reserve for focal disease (adenomyoma) if medical/IVF approaches fail

My Recommendation:

• Refer to reproductive medicine specialist for comprehensive fertility assessment (ovarian reserve, tubal patency via HSG, full hormonal profile)
• Discuss IVF as most efficient route given age and duration of infertility
• Consider 2-3 months pre-treatment with GnRH agonist if adenomyosis felt to be significant factor (individualized decision with fertility team)
• Realistic expectations: Success is achievable but may require multiple cycles; manage expectations regarding increased miscarriage risk
• If achieves pregnancy: early viability scan at 6-7 weeks; monitor for complications (though risk likely low with mild disease)

Empathy and Support: Acknowledge distress; provide written information; connect with support groups; emphasize team approach between gynaecology and reproductive medicine."

Viva Station 4: Differential Diagnosis

Question: "How do you distinguish adenomyosis from fibroids clinically and on imaging?"

Model Answer (use table format if possible):

Clinical Tip: On bimanual examination, fibroids feel like "a bag of marbles" (multiple discrete firm nodules); adenomyosis feels like "a waterlogged sponge" (diffusely soft and boggy).

Complication: They often coexist (50-70% of women with adenomyosis also have fibroids). MRI is invaluable in distinguishing and mapping both for surgical planning."

Viva Station 5: Management of Treatment Failure

Question: "A 46-year-old woman with adenomyosis has failed LNG-IUS (expelled twice), cannot tolerate COCP (migraines with aura), and had temporary improvement with GnRH agonist but symptoms recurred. She is significantly anaemic (Hb 82 g/L). What now?"

Model Answer: "This patient has failed multiple medical therapies and has significant anaemia indicating severe disease impact. She requires urgent management.

Immediate Management:

1. Treat anaemia: Oral iron (ferrous sulfate 200mg TDS) if tolerated; given severity (Hb 82), consider IV iron infusion (e.g., Ferinject) for rapid repletion
2. Assess haemodynamic stability: Symptomatic? (Dizziness, SOB, palpitations, chest pain); if haemodynamically compromised or Hb less than 70 g/L, consider blood transfusion
3. Stop bleeding: Short-term GnRH agonist or high-dose progestogen (e.g., norethisterone 5mg TDS continuous) to induce amenorrhoea while optimizing Hb and planning definitive management

Definitive Management: Given her age (46), failed medical therapies, and severe symptoms:

Option 1: Hysterectomy (Recommended)

• Only definitive cure; 95% symptom resolution; 85-95% satisfaction
• Age 46, likely completed family (confirm)
• Optimize preoperatively: Improve Hb (iron/transfusion); consider 3 months GnRH agonist to shrink uterus and improve anemia
• Approach: Total laparoscopic vs abdominal depending on uterine size, mobility, previous surgery
• Conserve ovaries (premenopausal; avoid surgical menopause)
• Risks: Standard surgical risks (bleeding, infection, VTE, bladder/ureteric injury 1-2%); counsel fully

Option 2: Uterine Artery Embolization

• If she strongly wishes to preserve uterus
• Less effective for adenomyosis than fibroids (60-75% improvement vs 85-95% for hysterectomy)
• 20-30% re-intervention rate within 2-5 years
• Risk of ovarian failure (10-15% at her age)
• Given severity of disease and prior treatment failures, UAE less likely to succeed but could be offered if she declines hysterectomy

Counselling:

• Acknowledge her previous challenges with treatments; validate her experience
• Explain hysterectomy is not 'giving up' but recognizing that definitive treatment is appropriate when medical options exhausted
• Address any fears/concerns about surgery, recovery, impacts
• Shared decision-making; provide written information; offer time to consider

Proceed: Once Hb optimized (aim > 100 g/L), list for surgery; ensure consent covers approach (may need open if technical factors), ovarian conservation, risks."

Model SBA Questions

Question 1: A 44-year-old woman presents with heavy menstrual bleeding. Transvaginal ultrasound shows a uniformly enlarged uterus with heterogeneous myometrium and myometrial cysts. What is the MOST appropriate first-line medical management?

A) Combined oral contraceptive pill
B) GnRH agonist (goserelin)
C) Levonorgestrel intrauterine system (Mirena)
D) Oral progestogen (norethisterone)
E) Tranexamic acid

Answer: C - Levonorgestrel IUS (Mirena) is first-line medical management for HMB including adenomyosis per NICE NG88. Reduces menstrual blood loss by 71-96%.

Question 2: On MRI, what junctional zone thickness is diagnostic for adenomyosis?

A) > 6mm
B) > 8mm
C) > 10mm
D) > 12mm
E) > 15mm

Answer: D - Junctional zone thickness > 12mm is diagnostic for adenomyosis (sensitivity 85-93%, specificity 91-96%).

Question 3: A 38-year-old woman with known adenomyosis and completed family has failed medical management. What is the ONLY definitive cure?

A) Endometrial ablation
B) Hysterectomy
C) Myomectomy
D) Uterine artery embolization
E) GnRH agonist with add-back HRT

Answer: B - Hysterectomy is the only definitive cure for adenomyosis. All other options provide symptomatic relief only (and endometrial ablation is contraindicated).

15. References

Primary Literature

1. Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus—revisited. Am J Obstet Gynecol. 1972;112(5):583-93. PMID: 4554562. DOI: 10.1016/0002-9378(72)90781-8

2. Struble J, Reid S, Bedaiwy MA. Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition. J Minim Invasive Gynecol. 2016;23(2):164-85. PMID: 26427702. DOI: 10.1016/j.jmig.2015.09.018

3. Naftalin J, Hoo W, Pateman K, et al. Is adenomyosis associated with menorrhagia? Hum Reprod. 2014;29(3):473-9. PMID: 24287817. DOI: 10.1093/humrep/det451

4. Bergholt T, Eriksen L, Berendt N, et al. Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod. 2001;16(11):2418-21. PMID: 11679529. DOI: 10.1093/humrep/16.11.2418

5. Vercellini P, Viganò P, Somigliana E, et al. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):465-77. PMID: 16563868. DOI: 10.1016/j.bpobgyn.2006.01.017

6. Dueholm M, Lundorf E, Hansen ES, et al. Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy. Fertil Steril. 2001;76(2):350-7. PMID: 11476784. DOI: 10.1016/s0015-0282(01)01900-8

7. Van den Bosch T, Dueholm M, Leone FP, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98. PMID: 25652685. DOI: 10.1002/uog.14806

8. Bazot M, Cortez A, Darai E, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod. 2001;16(11):2427-33. PMID: 11679531. DOI: 10.1093/humrep/16.11.2427

9. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2016;1:CD003855. PMID: 26820670. DOI: 10.1002/14651858.CD003855.pub3

10. Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113(5):1104-16. PMID: 19384127. DOI: 10.1097/AOG.0b013e3181a1d3ce

11. Sheng J, Zhang WY, Zhang JP, et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189-93. PMID: 19185672. DOI: 10.1016/j.contraception.2008.11.004

12. Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017;108(3):483-490.e3. PMID: 28865539. DOI: 10.1016/j.fertnstert.2017.06.034

13. Upson K, Missmer SA. Epidemiology of adenomyosis. Semin Reprod Med. 2020;38(2-03):89-107. PMID: 33176372. DOI: 10.1055/s-0040-1718920

14. Garcia-Solares J, Donnez J, Donnez O, et al. Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril. 2018;109(3):371-9. PMID: 29339031. DOI: 10.1016/j.fertnstert.2017.12.030

15. Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet. 2009;280(4):529-38. PMID: 19644696. DOI: 10.1007/s00404-009-1191-0

16. Vercellini P, Viganò P, Somigliana E, et al. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):465-77. PMID: 16563868. DOI: 10.1016/j.bpobgyn.2006.01.017

17. Harada T, Khine YM, Kaponis A, et al. The Impact of Adenomyosis on Women's Fertility. Obstet Gynecol Surv. 2016;71(9):557-68. PMID: 27640082. DOI: 10.1097/OGX.0000000000000346

18. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management (NG88). 2018 (updated 2021). Available at: https://www.nice.org.uk/guidance/ng88

Medical Disclaimer: MedVellum content is created for educational purposes and clinical reference for healthcare professionals and trainees. All clinical decisions must account for individual patient circumstances, current guidelines, and local protocols. Readers should consult appropriate specialists and verify information before applying clinically. Content is updated regularly but medical knowledge evolves; always refer to the most current evidence and guidelines.

Document Information:

• Lines: 1,044
• Citations: 18 PubMed-indexed references
• Last Updated: 2026-01-06
• Target Examination: MRCOG, FRANZCOG, Gynaecology Postgraduate Training